Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Potential Harms of rhGH Treatment to Patients With CF
Reports of potential harms investigated for the CER were related to known risk factors for disease encountered by patients with CF, such as altered glucose control and CFRD, and elevated risk for cancer of the digestive system. Other harms are associated with the use of rhGH, such as injection-site reactions and liver-function effects. Reports of any adverse event were noted.
Keywords: glucose | CFRD | CF-related diabetes | adverse events | blood glucose | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.